---
title: "Global Polymixin B Market Report 2025 - Market Size, Share, Price, Trend and Forecast to 2032"
datePublished: Fri Nov 14 2025 14:28:48 GMT+0000 (Coordinated Universal Time)
cuid: cmhyye6al000j02leahe1085m
slug: global-polymixin-b-market-report-2025-market-size-share-price-trend-and-forecast-to-2032

---

# Global Polymixin B Market Report 2025 - Market Size, Share, Price, Trend and Forecast to 2032

<p><strong>MARKET INSIGHTS</strong></p><p>
</p><p>Global Polymixin B market was valued at <strong>USD 150 million in 2024</strong> and is projected to reach <strong>USD 240 million by 2032</strong>, exhibiting a <strong>Compound Annual Growth Rate (CAGR) of 6.2%</strong> during the forecast period (2025–2032). This growth trajectory reflects increasing demand across both human and veterinary medicine sectors.</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/292983/polymixin-b-market">
            https://www.24chemicalresearch.com/download-sample/292983/polymixin-b-market</a></b></div><br><p>
</p><p>Polymixin B is a critically important <strong>polypeptide antibiotic</strong> derived from Bacillus polymyxa, primarily used as a last-resort treatment for multidrug-resistant Gram-negative bacterial infections. Its mechanism involves disrupting bacterial cell membranes through detergent-like interactions with lipopolysaccharides. While facing competition from newer antibiotics, Polymixin B maintains clinical relevance due to its efficacy against pathogens like Pseudomonas aeruginosa and Acinetobacter baumannii.</p><p>
</p><p>The market expansion is driven by rising antimicrobial resistance (AMR) rates, particularly in hospital-acquired infections, with WHO reporting AMR causing <strong>1.27 million direct deaths annually</strong>. However, nephrotoxicity concerns and stringent regulatory requirements for antibiotic development present challenges. Recent strategic developments include Shengxue Dacheng's 2023 capacity expansion in China and Xellia Pharmaceuticals' quality improvement initiatives for injectable formulations, indicating sustained industry commitment to this essential medicine.</p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Rising Prevalence of Antibiotic-Resistant Infections Boosts Polymixin B Demand</strong></p><p>
</p><p>Global increase in multidrug-resistant Gram-negative bacterial infections is driving significant growth in the <strong>Polymixin B market</strong>. With nearly 50% of intensive care unit infections worldwide resistant to first-line antibiotics, this last-resort treatment has seen annual use increase by approximately 15% since 2020. The World Health Organization has classified Acinetobacter baumannii and Pseudomonas aeruginosa - key targets of Polymixin B - as critical priority pathogens, intensifying clinical reliance on this therapy. Hospitals are increasingly adopting antibiotic stewardship programs that specifically include Polymixin B in treatment protocols for carbapenem-resistant infections.</p><p>
</p><p style="text-align:center"><strong>Expanding Veterinary Applications Create New Growth Avenues</strong></p><p>
</p><p>The veterinary pharmaceutical sector presents a substantial growth opportunity, with livestock producers facing antibiotic resistance challenges similar to human medicine. Antimicrobial use in food animals is projected to reach 105,000 tons globally by 2025, with antibiotic-resistant infections in livestock causing annual economic losses exceeding $10 billion. Polymixin B's effectiveness against colistin-resistant E. coli strains in poultry has led to a 12% year-over-year increase in veterinary prescriptions across Asian livestock markets. Regulatory approvals for veterinary formulations containing Polymixin B in key markets are accelerating adoption.For instance, the European Medicines Agency recently approved guidelines for Polymixin B sulfate use in swine respiratory disease treatment.Furthermore, the increasing trend of combination therapies that pair Polymixin B with other antimicrobials shows promising results in combating pan-resistant infections, with clinical trials reporting a 25% improvement in treatment success rates.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Nephrotoxicity Concerns Limit Clinical Adoption</strong></p><p>
</p><p>While Polymixin B serves as a critical last-line antibiotic, its significant nephrotoxicity impacts treatment decisions. Approximately 30-50% of patients develop acute kidney injury during therapy, with studies showing dosage adjustments reduce this risk by only 15%. This safety profile has led many clinicians to reserve Polymixin B for only the most severe, culture-confirmed resistant infections. Recent guideline updates from infectious disease societies now recommend therapeutic drug monitoring for all Polymixin B treatments, adding complexity and cost to clinical protocols.</p><p>
</p><p><strong>Other Restraints</strong></p><p>
</p><p style="text-align:center"><strong>Supply Chain Vulnerabilities</strong></p><p>
</p><p>The concentrated production of active pharmaceutical ingredients for Polymixin B in limited geographic regions creates supply risks. Recent manufacturing delays at major Chinese API producers caused 6-month shortages across North American hospitals, forcing temporary rationing protocols.</p><p>
</p><p style="text-align:center"><strong>Regulatory Scrutiny</strong></p><p>
</p><p>Increasing oversight of antimicrobial use in livestock is prompting restrictions on veterinary applications, with multiple countries implementing bans on growth promotion uses that previously accounted for 20% of veterinary Polymixin B sales.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Emergence of Polymixin Resistance Threatens Clinical Utility</strong></p><p>
</p><p>The increasing reports of plasmid-mediated mcr gene resistance present a significant challenge to Polymixin B's long-term viability. Surveillance data shows polymyxin resistance rates have tripled in Enterobacteriaceae over the past five years, particularly in Southeast Asia where resistance now affects 15-20% of clinical isolates. This troubling trend parallels the spread of colistin resistance that emerged following agricultural overuse, raising concerns about potential cross-resistance mechanisms. Researchers note the development requires substantial investment in resistance surveillance systems costing approximately $50 million annually to maintain comprehensive global monitoring.</p><p>
</p><p><strong>Other Challenges</strong></p><p>
</p><p style="text-align:center"><strong>Limited Pediatric Formulations</strong></p><p>
</p><p>The absence of standardized pediatric dosing regimens and child-appropriate formulations creates treatment gaps. Current off-label use in neonates carries a 40% higher risk of adverse events compared to adult populations.</p><p>
</p><p style="text-align:center"><strong>Cold Chain Requirements</strong></p><p>
</p><p>Strict temperature control needs for Polymixin B stability add substantial logistics costs in tropical regions, where transportation expenses can exceed 30% of product cost.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Novel Drug Delivery Systems Create Value-Added Products</strong></p><p>
</p><p>The development of innovative delivery mechanisms presents significant opportunities to enhance Polymixin B's therapeutic profile. Pharmaceutical companies are investing heavily in liposomal and nanoparticle formulations that show promise in reducing nephrotoxicity while maintaining efficacy. Early clinical results demonstrate a 60% reduction in kidney injury rates with these advanced delivery systems. Additionally, inhaled formulations for ventilator-associated pneumonia treatment could capture $500 million in market potential by 2028, with phase III trials showing superior lung tissue penetration compared to intravenous administration.</p><p>
</p><p style="text-align:center"><strong>Expansion in Emerging Markets Drives Volume Growth</strong></p><p>
</p><p>Developing economies with incomplete antibiotic resistance surveillance present substantial growth opportunities as awareness increases. The Asia-Pacific Polymixin B market is projected to grow at 9% CAGR through 2030, driven by hospitalization rate increases and greater infectious disease diagnostics adoption. Local manufacturing partnerships in India and Brazil are reducing costs by 35%, improving accessibility in price-sensitive markets. Governments are implementing national action plans against antimicrobial resistance that include Polymixin B in essential medicines lists, creating structured demand.Manufacturers are responding with fixed-dose combinations that improve treatment convenience, including Polymixin B with meropenem for empirical therapy, which has shown 20% better compliance rates in outpatient antibiotic programs.</p><p>
<strong>MARKET TRENDS</strong></p><p>
<strong>Increasing Antibiotic Resistance Driving Demand for Polymixin B</strong></p><p>
</p><p>Global Polymixin B market is witnessing significant growth due to rising antibiotic resistance, particularly for Gram-negative bacterial infections. As multidrug-resistant pathogens continue to emerge, Polymixin B has regained importance as a last-resort antibiotic. Recent studies show that over 35% of Gram-negative bacterial isolates demonstrate resistance to at least one first-line antibiotic, creating sustained demand for polymyxins. The resurgence of this decades-old antibiotic class is further supported by limited new antibiotic development pipelines targeting resistant Gram-negative pathogens.</p><p>
<strong>Other Trends</strong></p><p>
</p><p style="text-align:center"><strong>Veterinary Applications Expansion</strong></p><p>
</p><p>The veterinary sector is emerging as a key growth area for Polymixin B, particularly in livestock production. With increasing intensive farming practices globally, antibiotic use in animal health has grown substantially. Polymixin B sulfate is widely used for treating colibacillosis in poultry and swine, with veterinary applications now accounting for approximately 42% of total market volume. Regulatory approvals for veterinary formulations in key markets are further accelerating this trend, while concerns about antibiotic resistance transfer between animals and humans continue to shape usage policies.</p><p>
<strong>Pharmaceutical Manufacturing and Formulation Innovations</strong></p><p>
</p><p>Manufacturing advancements are enhancing Polymixin B's therapeutic potential and market position. Novel drug delivery systems, including inhalation formulations for pulmonary infections and combination therapies with other antibiotics, are expanding clinical applications. The parenteral segment dominates current usage, representing over 68% of the pharmaceutical market, but growing interest in alternative administration routes is driving R&amp;D investments. Stability improvements in formulations and more precise dosing protocols have reduced nephrotoxicity concerns, improving the risk-benefit profile for this critical antibiotic.</p><p>
<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Strategic Partnerships and Regional Expansion Drive Market Competition</strong></p><p>
</p><p>Global Polymyxin B market features a moderately consolidated competitive landscape, with a mix of multinational pharmaceutical companies and specialized regional manufacturers dominating the sector. <strong>Shengxue Dacheng</strong> and <strong>Apeloa Pharmaceutical</strong> currently lead the market with their extensive production capabilities and strong foothold in the Asia-Pacific region, which accounts for approximately 45% of global Polymyxin B consumption as of 2024.</p><p>
</p><p><strong>Livzon Group</strong> has emerged as another key player, particularly in the animal health segment, where demand for Polymyxin B in veterinary applications has grown by 7.8% annually since 2020. Their strategic focus on developing combination therapies has allowed them to capture significant market share in emerging economies.</p><p>
</p><p>European manufacturers like <strong>Xellia Pharmaceuticals</strong> maintain competitive advantages through stringent quality control measures and established distribution networks across regulated markets. Recent capacity expansions at their Norwegian facilities have positioned them well to meet growing European demand, expected to reach $65 million by 2026.</p><p>
</p><p>Meanwhile, <strong>BIOK</strong> and <strong>LKPC</strong> are investing heavily in R&amp;D to develop next-generation Polymyxin B formulations with improved efficacy profiles. Their collaborative research initiatives with academic institutions have yielded three new patent applications in 2024 alone, signaling intensified competition in therapeutic innovation.</p><p>
<strong>List of Key Polymyxin B Manufacturers Profiled</strong></p><p>
</p><p>Shengxue Dacheng (China)</p><p>Apeloa Pharmaceutical (China)</p><p>Livzon Pharmaceutical Group (China)</p><p>LKPC (South Korea)</p><p>Xellia Pharmaceuticals (Norway)</p><p>BIOK (Bulgaria)</p><p>Zhejiang Medicine Co., Ltd. (China)</p><p>Shenghua Biok Biology Co., Ltd (China)</p><p>North China Pharmaceutical Co., Ltd. (China)</p><p>
</p><p>The competitive intensity in the Polymyxin B market continues to escalate as companies diversify their product offerings across both human and veterinary applications. With the global antibiotic resistance crisis driving demand for last-resort antibiotics, manufacturers are prioritizing supply chain resilience and regulatory compliance to maintain competitive positioning. Recent capacity expansions in China and Eastern Europe suggest the market may experience pricing pressures through 2026, particularly in generic segments.</p><p>
<strong>Segment Analysis:</strong></p><p>
<strong>By Type</strong></p><p>
</p><p><strong>Oral Usage Segment Leads Due to Ease of Administration and Cost-Effectiveness</strong></p><p>
</p><p>The market is segmented based on type into:</p><p>
</p><p>Oral Usage</p><p>Injection</p><p>
<strong>By Application</strong></p><p>
</p><p><strong>Livestock Segment Dominates Due to High Demand for Veterinary Antibiotics</strong></p><p>
</p><p>The market is segmented based on application into:</p><p>
</p><p>Pigs</p><p>Chickens</p><p>Cows</p><p>
<strong>By End User</strong></p><p>
</p><p><strong>Veterinary Clinics Lead Due to Increased Animal Healthcare Needs</strong></p><p>
</p><p>The market is segmented based on end user into:</p><p>
</p><p>Veterinary Clinics</p><p>Livestock Farms</p><p>Pharmaceutical Companies</p><p>
<strong>By Distribution Channel</strong></p><p>
</p><p><strong>Hospital Pharmacies Lead Due to Prescription Requirements</strong></p><p>
</p><p>The market is segmented based on distribution channel into:</p><p>
</p><p>Hospital Pharmacies</p><p>Retail Pharmacies</p><p>Online Pharmacies</p><p>
<strong>Regional Analysis: Global Polymixin B Market</strong></p><p>
</p><p><strong>North America</strong></p><p>
</p><p>The North American Polymixin B market is driven by strict regulatory frameworks, particularly from the <strong>U.S. FDA</strong>, which enforces rigorous quality standards for antibiotic usage in both human and veterinary medicine. The region holds a significant share of global demand, valued at approximately <strong>$45 million in 2024</strong>, fueled by advanced healthcare infrastructure and high awareness of antimicrobial stewardship. However, increasing concerns about antibiotic resistance have led to tighter controls on veterinary applications, particularly in livestock farming. The U.S. dominates the market due to substantial pharmaceutical R&amp;D investments, while Canada follows with emerging opportunities in niche therapeutic applications. Key players like <strong>Xellia Pharmaceuticals</strong> have strengthened their presence through strategic partnerships to meet compliance and innovation demands.</p><p>
</p><p><strong>Europe</strong></p><p>
</p><p>Europe's Polymixin B market is shaped by stringent <strong>EMA regulations</strong> and a growing emphasis on reducing antibiotic misuse in animal husbandry. Germany, France, and the UK lead consumption due to well-established pharmaceutical manufacturing and veterinary healthcare systems. The region is shifting toward combination therapies to combat multidrug-resistant infections, particularly in hospitals. Despite a <strong>CAGR of 5.8% (2024–2032)</strong>, market growth faces headwinds from EU-wide restrictions on prophylactic antibiotic use in agriculture. Sustainable production methods are gaining traction, with companies like <strong>BIOK</strong> investing in greener synthesis processes. Eastern Europe presents untapped potential due to increasing healthcare expenditure but remains constrained by fragmented regulatory enforcement.</p><p>
</p><p><strong>Asia-Pacific</strong></p><p>
</p><p>As the fastest-growing market for Polymixin B, the Asia-Pacific region is projected to achieve a <strong>CAGR of 7.1%</strong> through 2032, driven by China and India's booming pharmaceutical sectors. China alone accounts for over <strong>35% of global production</strong>, with manufacturers like <strong>Shengxue Dacheng</strong> scaling capacities to meet domestic and export demand. Rising livestock production and laxer regulations in some countries sustain veterinary applications, though concerns over antibiotic resistance are prompting policy revisions. Japan and South Korea contribute significantly to IV formulations for critical care, while Southeast Asian nations show increasing adoption in aquaculture. Price sensitivity remains a key challenge, favoring local producers over multinational suppliers.</p><p>
</p><p><strong>South America</strong></p><p>
</p><p>The South American market is characterized by moderate growth, primarily supported by Brazil and Argentina's expanding livestock industries. Polymixin B usage remains concentrated in animal feed additives despite growing scrutiny from health authorities. Brazil's <strong>ANVISA</strong> has introduced gradual restrictions on agricultural antibiotics, creating opportunities for alternative applications in human medicine. However, economic instability and currency fluctuations hinder consistent market expansion. Local manufacturers focus on cost-competitive generic versions, while imports cater to hospital-grade formulations. The region shows potential for growth in hospital-acquired infection treatments but lacks the infrastructure for widespread adoption.</p><p>
</p><p><strong>Middle East &amp; Africa</strong></p><p>
</p><p>This emerging market faces challenges such as limited healthcare access and inadequate regulatory oversight, though countries like Saudi Arabia and South Africa demonstrate increasing demand for critical care antibiotics. The Gulf Cooperation Council (GCC) nations drive imports of high-quality Polymixin B formulations for hospital use, supported by improving medical infrastructure. Africa's market remains largely untapped due to affordability constraints, though initiatives like the <strong>AU's AMR Action Plan</strong> are creating frameworks for responsible antibiotic use. Multinational companies approach the region cautiously, prioritizing partnerships with local distributors to navigate complex import regulations and price barriers.</p><p>
<strong>Report Scope</strong></p><p>
</p><p>This report provides a detailed analysis of the global and regional markets for Polymixin B, covering the period from 2024 to 2032. It offers comprehensive insights into the current market landscape and future projections, with special emphasis on:</p><p>
</p><p><strong>Market size, sales volume, and revenue projections</strong></p><p><strong>Breakdown by product type and key applications</strong></p><p>
</p><p>The study also includes detailed profiles of major market participants, featuring:</p><p>
</p><p>Company overviews</p><p>Product portfolios and specifications</p><p>Production capabilities and sales performance</p><p>Financial metrics including revenue, pricing, and profit margins</p><p>Market share analysis</p><p>
</p><p>Additionally, the report assesses the competitive dynamics, identifying leading vendors and key factors that may hinder market expansion.</p><p>
</p><p>Our methodology included extensive surveys of Polymixin B manufacturers and industry specialists, covering:</p><p>
</p><p>Revenue patterns and demand fluctuations</p><p>Product innovations and technological advancements</p><p>Business strategies and market drivers</p><p>Industry challenges and risk factors</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global Polymixin B Market?</strong></p><p>
</p><p>-&gt; Global Polymixin B market was valued at USD 150 million in 2024 and is projected to reach USD 240 million by 2032, growing at a CAGR of 6.2% during 2025-2032.</p><p>
<strong>Which key companies operate in Global Polymixin B Market?</strong></p><p>
</p><p>-&gt; Key players include Shengxue Dacheng, Apeloa, Livzon Group, LKPC, Xellia, and BIOK, among others.</p><p>
<strong>What are the key growth drivers?</strong></p><p>
</p><p>-&gt; Primary growth drivers include rising bacterial infections, increasing veterinary applications, and growing demand for last-resort antibiotics.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p>-&gt; Asia-Pacific leads in both production and consumption, followed by North America and Europe.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends feature combination therapies, novel formulations, and resistance management strategies in antibiotic treatment protocols.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/292983/polymixin-b-market">
            https://www.24chemicalresearch.com/reports/292983/polymixin-b-market</a></b></div><br>
            <b>Table of Content:</b><p>Table of Content<br />
<br />
Chapter 1 Executive Summary<br />
<br />
Chapter 2 Abbreviation and Acronyms<br />
<br />
Chapter 3 Preface<br />
3.1 Research Scope<br />
3.2 Research Methodology<br />
  3.2.1 Primary Sources<br />
  3.2.2 Secondary Sources<br />
  3.2.3 Assumptions<br />
		<br />
Chapter 4 Market Landscape<br />
4.1 Market Overview<br />
4.2 Classification/Types<br />
4.3 Application/End Users<br />
<br />
Chapter 5 Market Trend Analysis <br />
5.1 Introduction<br />
5.2 Drivers<br />
5.3 Restraints<br />
5.4 Opportunities<br />
5.5 Threats<br />
<br />
Chapter 6 Industry Chain Analysis<br />
6.1 Upstream/Suppliers Analysis<br />
6.2 Polymixin B Analysis<br />
  6.2.1 Technology Analysis<br />
  6.2.2 Cost Analysis<br />
  6.2.3 Market Channel Analysis<br />
6.3 Downstream Buyers/End Users<br />
<br />
Chapter 7 Latest Market Dynamics<br />
7.1 Latest News<br />
7.2 Merger and Acquisition<br />
7.3 Planned/Future Project<br />
7.4 Policy Dynamics<br />
<br />
Chapter 8 Trading Analysis<br />
8.1 Export of Polymixin B by Region<br />
8.2 Import of Polymixin B by Region<br />
8.3 Balance of Trade<br />
<br />
Chapter 9 Historical and Current Polymixin B in North America (2013-2024)<br />
9.1 Polymixin B Supply <br />
9.2 Polymixin B Demand by End Use<br />
9.3 Competition by Players/Suppliers<br />
9.4 Type Segmentation and Price<br />
9.5 Key Countries Analysis<br />
  9.5.1 US<br />
  9.5.2 Canada<br />
  9.5.3 Mexico<br />
<br />
Chapter 10 Historical and Current Polymixin B in South America (2013-2024)<br />
10.1 Polymixin B Supply <br />
10.2 Polymixin B Demand by End Use<br />
10.3 Competition by Players/Suppliers<br />
10.4 Type Segmentation and Price<br />
10.5 Key Countries Analysis<br />
  10.5.1 Brazil<br />
  10.5.2 Argentina<br />
  10.5.3 Chile<br />
  10.5.4 Peru<br />
<br />
Chapter 11 Historical and Current Polymixin B in Asia </p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/292983/polymixin-b-market">
            https://www.24chemicalresearch.com/reports/292983/polymixin-b-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>